FNP-223 is currently being investigated in a phase 2 trial evaluating the treatment in adults with possible or probable PSP-Richardson syndrome.

“We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our ...

In PSP patients, depression and anxiety—not motor symptoms—were most strongly linked to lower quality of life, highlighting the importance of mood symptom management in clinical care.

Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems 2-4. PSP has a prevalence of approximately 5 cases per ...

Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems 2-4.

Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems 2-4.PSP has a prevalence of approximately 5 cases per ...

Background Progressive supranuclear palsy and Parkinson's disease have characteristic clinical and neuropathologic profiles, but also share overlapping clinical features. This study aimed to ...

"We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our ...

Kinetic measures of a cerebrospinal fluid (CSF) biomarker test predicted cognitive decline in Parkinson's disease and ...

Distinct patterns of brain inflammation identified through PET imaging may explain disease progression and severity in ...

A national charity has claimed that Dorset residents with two specific complex and life-limiting conditions are less likely to receive NHS continuing healthcare (CHC) funding than those with similar ...